Contact Us
Drug Search Results
More Filters [+]

ILB-3101

Alternative Names: ILB-3101, ILB 3101, ILB3101
Latest Update: 2024-05-24
Latest Update Note: Clinical Trial Update

Product Description

ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. (Sourced from: https://clinicaltrials.gov/study/NCT06426680)

Mechanisms of Action: B7-H3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innolake Biopharm
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ILB-3101

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Esophageal Cancer|Head and Neck Cancer|Ovarian Cancer|Prostate Cancer|Small Cell Lung Cancer|Small Cell Sarcoma|Soft Tissue Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CILB3101A101

P1

Not yet recruiting

Soft Tissue Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Prostate Cancer|Small Cell Sarcoma|Uterine Cancer|Esophageal Cancer|Ovarian Cancer

2025-12-01

44%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions